AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019

Ditsch, Nina; Untch, Michael; Thill, Marc; Müller, Volkmar; Janni, Wolfgang; Albert, Ute‐Susann; Bauerfeind, Ingo; Blohmer, Jens-Uwe; Budach, Wilfried; Dall, P.; Diel, Ingo J.; Fasching, Peter A.; Fehm, Tanja; Friedrich, Michael; Gerber, Bernd; Hanf, Volker; Harbeck, Nadia; Huober, Jens; Jackisch, Christian; Kolberg-Liedtke, Cornelia; Kreipe, Hans-Heinrich; Krug, David; Kühn, Thorsten; Kümmel, Sherko; Loibl, Sibylle; Lüftner, Diana; Lux, Michael P.; Maass, Nicolaì; Möbus, V.; Müller-Schimpfle, Markus; Mundhenke, Christoph; Nitz, Ulrike; Rhiem, Kerstin; Rody, Achim; Schmidt, Marcus; Schneeweiß, Andreas; Schütz, Florian; Sinn, Hans‐Peter; Solbach, Christine; Solomayer, Erich‐Franz; Stickeler, Elmar; Thomssen, Christoph; Wenz, Frederik; Witzel, Isabell; Wöckel, Achim

doi:10.1159/000501000

Cited by 73 publications

(137 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multigene signature testing remains restricted to cases in which a clear therapy decision cannot be made based on all other criteria. 7,8 NACT was used initially to enable or improve the operability of breast tumors that were large, inflammatory, or locally advanced. This approach offers several benefits compared to ACT.…”

mentioning

confidence: 99%

Time trends of neoadjuvant chemotherapy for early breast cancer

Riedel

Hoffmann

Moderow

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NACT) in early breast cancer (EBC) enables in vivo sensitivity testing and less radical surgery as compared to primary surgery and adjuvant chemotherapy (ACT). The aim of our study is to illustrate trends of systemic treatment of EBC. The study analyzed chemotherapy usage and time trends for patients with EBC treated at 104 German breast units between January 2008 and December 2017. The data were obtained through a quality-controlled benchmarking process. Altogether, 124 084 patients were included, of whom 46 279 (37.3%) received chemotherapy. For 44 765 of these cases, detailed information on systemic treatment and surgery were available. Overall use of chemotherapy declined from 42.0% in 2008 to 32.0% in 2017. During that same time, the proportion of NACT increased from 20.0% to 57.7%, irrespective of tumor subtype. The pathological complete response (pCR) rate (defined as ypT0 ypN0) at surgery after NACT increased from 15.0% to 34.2%. The results from this large cohort from the clinical routine reflect the refined indications for chemotherapy in EBC.

show abstract

mentioning

confidence: 99%

Time trends of neoadjuvant chemotherapy for early breast cancer

Riedel

Hoffmann

Moderow

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another chemotherapy toxicity is ovarian insufficiency in premenopausal patients. Here the addition of GnRH analogues to chemotherapy independent of hormone receptor status can be considered [32]. Currently the OPTION study with 227 premenopausal patients with early breast cancer in whom quality of life with and without GnRH analogues on chemotherapy was documented at the start of therapy, after 3, 6, 12, 18, 24 months and then every 5 years demonstrated a significant worsening in quality of life on chemotherapy due to increased menopausal symptoms (p = 0.02) [33].…”

Section: Therapy Cohortsmentioning

confidence: 99%

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics

Lüftner

Schneeweiß

Hartkopf

et al. 2020

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.

show abstract

“…Genetische Testungen von Keimbahnmutationen sind Teil der Routineversorgung bei Patientinnen mit einer Indikation für eine genetische Testung geworden [1][2][3][4][5]. Die beiden Gene, die klinisch am relevantesten sind, sind Breast Cancer 1 (BRCA1) und BRCA2 [6].…”

Section: Genetische Testungen Für Hoch Penetrante Und Moderat Penetraunclassified

Update Mammakarzinom 2020 Teil 1 – frühes Mammakarzinom: Konsolidierung des Wissens über bekannte Therapien

Schneeweiß

Hartkopf

Müller

et al. 2020

Senologie - Zeitschrift für Mammadiagnostik und -therapie

Self Cite

View full text Add to dashboard Cite

ZusammenfassungIn dieser Übersichtsarbeit werden die neuesten Entwicklungen in der Prävention und in der Behandlung des frühen Mammakarzinoms dargestellt. Mit großen epidemiologischen Studien zu genetischen und nicht genetischen Risikofaktoren wird das Brustkrebsrisiko immer besser beschreibbar. Durch neue Analysen konnte sowohl die Evidenz für hoch penetrante Gene als auch für niedrig penetrante Gene verbessert werden. Neue Daten zu Denosumab und Atezolizumab liegen in der Neoadjuvanz vor, genauso wie eine gepoolte Auswertung zahlreicher Studien zu Capecitabin in der kurativen Situation. Ebenso gibt es eine Aktualisierung der Gesamtüberlebensdaten von Pertuzumab in der Adjuvanz mit einer längeren Nachbeobachtungszeit. Letztlich hält die digitale Medizin stetigen Einzug in die Wissenschaft. Eine kürzlich durchgeführte Studie zur automatisierten Brustkrebserkennung mittels künstlicher Intelligenz schafft die Grundlagen für eine künftige Überprüfung in klinischen Studien.

show abstract

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019

Cited by 73 publications

References 147 publications

Time trends of neoadjuvant chemotherapy for early breast cancer

Time trends of neoadjuvant chemotherapy for early breast cancer

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics

Update Mammakarzinom 2020 Teil 1 – frühes Mammakarzinom: Konsolidierung des Wissens über bekannte Therapien

Contact Info

Product

Resources

About